<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">OJGas</journal-id><journal-title-group><journal-title>Open Journal of Gastroenterology</journal-title></journal-title-group><issn pub-type="epub">2163-9450</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.4236/ojgas.2017.78024</article-id><article-id pub-id-type="publisher-id">OJGas-78831</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Medicine&amp;Healthcare</subject></subj-group></article-categories><title-group><article-title>
 
 
  Pancreatic Cancer: Epidemiological, Clinical and Therapeutic Aspects in Abidjan (Ivory Coast)
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Amadou</surname><given-names>Ouattara</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Siaka</surname><given-names>Kone</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Dramane</surname><given-names>Soro</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Constant</surname><given-names>Assi</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Emile</surname><given-names>Allah-Kouadio</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Rodrigue</surname><given-names>Irie Gohi Bi</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Fanoucoffi</surname><given-names>Denis</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Marie-Jeanne</surname><given-names>Lohoues-Kouacou</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff1"><addr-line>Teaching Hospital Center of Cocody, Abidjan, C&amp;amp;ocirc;te d’Ivoire</addr-line></aff><author-notes><corresp id="cor1">* E-mail:<email>drouattara2009@yahoo.fr(AO)</email>;</corresp></author-notes><pub-date pub-type="epub"><day>15</day><month>08</month><year>2017</year></pub-date><volume>07</volume><issue>08</issue><fpage>223</fpage><lpage>229</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  Aim: The aim was to study the epidemiological, clinical and therapeutic aspects of pancreatic cancers in Ivory Coast. 
  Materials and methods: A retrospective multi-center and multidisciplinary study aimed at describing sixteen years and four months from January 1, 2000 to April 30, 2016 in several hospitals in the city of Abidjan taking charge of pancreatic cancers (hepato-gas troenterology services of the universities hospitals of Cocody and Yopougon), internal medicine departments of University Hospital of Treichville and Abidjan Military Hospital, the department of oncology of the university hospital center of Treichville, private clinics (DANGA, PISAM and GMP), the COBA center in Treichville. The diagnosis of cancer was based on either histological criteria or a set of clinical and paraclinical arguments. Patients whose files did not include imaging were excluded from this study. The following parameters were collected: age, sex, reason for consultation, physical signs, personal and family antecedents, tumor characteristics, delay in diagnosis and the nature of the treatment administered. 
  Results: We have observed 150 cases of pancreatic cancer. The mean age of patients was 59.09 years with extremes ranging from 24 years to 88 years. Our study population consisted of 98 men and 52 women (sex ratio 1.88). Risk factors were dominated by diabetes 20.7%. Epigastralgia is the main reason for consultation (48%). The tumor was localized at the cephalic level in 84.67%. In 13 cases the diagnosis was histological and was dominated by adenocarcinoma (100%). The majority of our patients was seen at an advanced stage of the disease: stage IV (74.56%). The average time to diagnosis was 2.76 months. Fourteen of our patients (9.33%) had benefited surgery. This was curative surgery in 35.71% (n = 5) and palliative in 64.29% (n = 9). Among those who benefited from this curative surgery, three died two months after surgery and two lost to follow-up. The majority (90.67%) of our patients had received symptomatic treatment. 
  Conclusion: Pancreatic cancer is an appalling cancer with a very bad and late diagnosis because of its insidious symptomatology. Most of the time, tumors had already metastasized before diagnosis, so the treatment is often symptomatic.
 
</p></abstract><kwd-group><kwd>Pancreas</kwd><kwd> Cancer</kwd><kwd> Epidemiological</kwd><kwd> Ivory Coast</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>1. Introduction</title><p>Pancreatic cancer is a tumor developed at the expense of pancreatic tissue [<xref ref-type="bibr" rid="scirp.78831-ref1">1</xref>] . This neoplasm represents the eighth leading cause of death in neoplasia worldwide [<xref ref-type="bibr" rid="scirp.78831-ref2">2</xref>] . It is an appalling cancer because of the high mortality rate associated with delayed diagnosis. It is a tumor whose symptomatology is not very specific and of insidious evolution. Its clinical manifestation consists of jaundice associated with an alteration of the general condition. The appearance of these clinical manifestations testifies most often of an advanced stage of the disease.</p><p>The prevalence of this cancer in the world is disparate. It is higher in some areas known as high prevalence areas (United States of America, New Zealand, Korea) and low in other areas called low prevalence areas (India, Tanzania, Guinea) [<xref ref-type="bibr" rid="scirp.78831-ref3">3</xref>] . In Africa few studies have been devoted to this pathology, being considered formerly rare [<xref ref-type="bibr" rid="scirp.78831-ref4">4</xref>] - [<xref ref-type="bibr" rid="scirp.78831-ref9">9</xref>] . Today its incidence tends to increase due to increased exposure to alcohol-tobacco intoxication and the rise of medical imaging. In Ivory Coast there are no studies on this disease. We initiated this study, the aim of which was to study the epidemiological, clinical and therapeutic aspects of pancreatic cancers in Ivory Coast.</p></sec><sec id="s2"><title>2. Materials and Methods</title><p>A retrospective multi-center and multidisciplinary study aimed at describing sixteen-years and four months from 01 January 2000 to 30 April 2016 in several hospitals in the city of Abidjan taking charge of pancreatic cancers (hepato-gas- troenterology services of the universities hospitals of Cocody and Yopougon, internal medicine departments of University Hospital of Treichville and Abidjan Military Hospital, the department of oncology of the university hospital center of Treichville, private clinics (DANGA, PISAM and GMP), the COBA center at Treichville. The diagnosis of cancer was based on either histological criteria or a set of clinical and paraclinical arguments [cholestatic jaundice, altered general condition, large palpated vesicle, presence of an ogive, morphological abnormalities (heterogeneous mass of the pancreas, dilation of the Wirsung duct and choledochus) Dosage of tumor markers]. Patients whose files did not include imaging were excluded from this study. The following parameters (age, sex, reason for consultation, physical signs, personal and family antecedents, tumor characteristics, delay in diagnosis and the nature of the treatment administered) were compiled on survey forms and analyzed on the IBM SPSS statistic version 20 software.</p></sec><sec id="s3"><title>3. Results</title><p>During the study period we observed 150 cases of pancreatic cancers. The mean age of patients was 59.09 years with extremes ranging from 24 years to 88 years. Our study population consisted of 98 men and the risk factors were dominated by diabetes (20.7%) (<xref ref-type="table" rid="table1">Table 1</xref>).... Epigastralgia, the main reason for consultation (48%) was typical in nearly half of our patients (47.22%), followed by jaundice (44.7%) (<xref ref-type="table" rid="table2">Table 2</xref>). The tumor was localized at the cephalic level in 84.67% of the cases (n = 127) (<xref ref-type="table" rid="table3">Table 3</xref>). Only twelve of our patients (8%) had tumor markers. In 13 cases the diagnosis was histological and was dominated by adenocarcinoma</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Socio-demographic characteristics</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Variables</th><th align="center" valign="middle" >Frequency (n)</th><th align="center" valign="middle" >Percentage (%)</th></tr></thead><tr><td align="center" valign="middle" >Gender: Male Female Age: Middle age: 59.09 years &lt;40 years 40 - 59 years 60 - 79 years &gt;80 years Riskfactors: Diab&#232;tes Alcohol Tobacco Chronic pancr&#233;atitis Other family cancer Family diabetes Family pancreatic cancer</td><td align="center" valign="middle" >98 52 10 62 73 5 31 29 17 4 3 2 1</td><td align="center" valign="middle" >65.33 34.67 6.67 41.33 48.67 3.33 20.7 19.3 11.3 2.7 2 1.33 0.67</td></tr></tbody></table></table-wrap><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Distribution of patients according to the reason for consultation</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Reason for consultation</th><th align="center" valign="middle" >Frequency (n)</th><th align="center" valign="middle" >Percentage (%)</th></tr></thead><tr><td align="center" valign="middle" >Epigastralgia</td><td align="center" valign="middle" >72</td><td align="center" valign="middle" >48</td></tr><tr><td align="center" valign="middle" >Jaundice</td><td align="center" valign="middle" >67</td><td align="center" valign="middle" >44.7</td></tr><tr><td align="center" valign="middle" >Alteration in general condition</td><td align="center" valign="middle" >45</td><td align="center" valign="middle" >30</td></tr><tr><td align="center" valign="middle" >Abdominal mass</td><td align="center" valign="middle" >34</td><td align="center" valign="middle" >22.67</td></tr><tr><td align="center" valign="middle" >Pruritus</td><td align="center" valign="middle" >26</td><td align="center" valign="middle" >17.33</td></tr><tr><td align="center" valign="middle" >Vomiting</td><td align="center" valign="middle" >5</td><td align="center" valign="middle" >3.33</td></tr><tr><td align="center" valign="middle" >Ascites</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >2,67</td></tr><tr><td align="center" valign="middle" >Digestive bleeding</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >2</td></tr></tbody></table></table-wrap><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> Patient distribution according to the localization of the cancer</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Site</th><th align="center" valign="middle" >Frequency (n)</th><th align="center" valign="middle" >Percentage (%)</th></tr></thead><tr><td align="center" valign="middle" >Head</td><td align="center" valign="middle" >127</td><td align="center" valign="middle" >84.67</td></tr><tr><td align="center" valign="middle" >Tail</td><td align="center" valign="middle" >9</td><td align="center" valign="middle" >6</td></tr><tr><td align="center" valign="middle" >Body + Tail</td><td align="center" valign="middle" >8</td><td align="center" valign="middle" >5.33</td></tr><tr><td align="center" valign="middle" >Body</td><td align="center" valign="middle" >5</td><td align="center" valign="middle" >3.33</td></tr><tr><td align="center" valign="middle" >Head + Body</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >0.67</td></tr></tbody></table></table-wrap><table-wrap id="table4" ><label><xref ref-type="table" rid="table4">Table 4</xref></label><caption><title> Distribution of patients according to stage of cancer</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Stage of disease</th><th align="center" valign="middle" >Frequency (n)</th><th align="center" valign="middle" >Percentage (%)</th></tr></thead><tr><td align="center" valign="middle" >Stage IV</td><td align="center" valign="middle" >112</td><td align="center" valign="middle" >74.56</td></tr><tr><td align="center" valign="middle" >Stage III</td><td align="center" valign="middle" >28</td><td align="center" valign="middle" >18.67</td></tr><tr><td align="center" valign="middle" >Stage II</td><td align="center" valign="middle" >10</td><td align="center" valign="middle" >6.77</td></tr></tbody></table></table-wrap><p>(100%). The majority of our patients were seen at an advanced stage of the disease: Stage IV (74.56%) (<xref ref-type="table" rid="table4">Table 4</xref>). The average delay Diagnosis was 2.76 months. Fourteen of our patients (9.33%) had benefited a surgery. This surgery was curative in 35.71% of the cases (n = 5) including 4 cases of duodeno-pancreatectomy cephalic and a case of left spleno-pancreatectomy. In 64.29% (n = 9) it was palliative; It was a bilio-digestive derivation. Three cases of death two months after the operation and two cases of loss of follow-up were observed in patients who had benefited a curative surgery. The majority (90.66%) of our patients had received symptomatic treatment. It was analgesic level 2 (62.07%), morphinic (19.54%) and analgesic level 1 (18.39%).</p></sec><sec id="s4"><title>4. Discussion</title><p>The major limitations of our study were the low rate of histological results making diagnosis been almost radiological and poor record keeping responsible for a large number of unusable medical records.</p><p>Pancreatic cancer (150 cases over a period of 16-year and four months) was rare in our study. This low frequency was reported by several African authors. Thus Bouglouga in Togo [<xref ref-type="bibr" rid="scirp.78831-ref7">7</xref>] and Mbengue in Senegal [<xref ref-type="bibr" rid="scirp.78831-ref5">5</xref>] from medical records reported 30 cases of cancers over a period of 8 years and cases107 cases of cancers over a period of five and a half years. Moumen in Morocco [<xref ref-type="bibr" rid="scirp.78831-ref6">6</xref>] and El Guesmi in Tunisia [<xref ref-type="bibr" rid="scirp.78831-ref8">8</xref>] reported 160 cases of cancers over 9 years and 158 cases over a period of 13 years. AL-Majed in Asia [<xref ref-type="bibr" rid="scirp.78831-ref10">10</xref>] and Qiu [<xref ref-type="bibr" rid="scirp.78831-ref11">11</xref>] in the United States reported 276 cases of cancers in 10 years and 52,759 cases of cancers in eight years respectively. The high number of cancers in these developed countries could be explained by the current realization of abdominal echography and abdominal CT scan. The average age of our patients 59.09 years was close to that found by Moumen [<xref ref-type="bibr" rid="scirp.78831-ref6">6</xref>] in Morocco (60 years), Mbengue [<xref ref-type="bibr" rid="scirp.78831-ref5">5</xref>] in Senegal (60 years) and Al-Majed [<xref ref-type="bibr" rid="scirp.78831-ref10">10</xref>] . These data are in contradiction with those of Ntagirabiri [<xref ref-type="bibr" rid="scirp.78831-ref12">12</xref>] and Raissouni [<xref ref-type="bibr" rid="scirp.78831-ref9">9</xref>] . Those reported an average age of 50.3 years and 44 years respectively. The male predominance observed in our study was reported by Coulibaly [<xref ref-type="bibr" rid="scirp.78831-ref4">4</xref>] , Majid [<xref ref-type="bibr" rid="scirp.78831-ref13">13</xref>] and El Guesmi [<xref ref-type="bibr" rid="scirp.78831-ref8">8</xref>] . However, QIU [<xref ref-type="bibr" rid="scirp.78831-ref11">11</xref>] reported a slight female predominance. Our results showed that 20.7% of our patients were diabetic, 19.3% were alcoholics and 11.3% were cigarette smokers. Similar rates have been reported by several authors [<xref ref-type="bibr" rid="scirp.78831-ref9">9</xref>] [<xref ref-type="bibr" rid="scirp.78831-ref14">14</xref>] , which could represent a risk factor for pancreatic cancer. Diabetes appears to be a moderate risk factor for pancreatic cancer, with a 40% higher risk in diabetics than in non-diabetics. Those with a diabetes duration of 2 - 8 years had the highest risk; 1.8 times more likely to develop pancreatic cancer than non-diabetics [<xref ref-type="bibr" rid="scirp.78831-ref15">15</xref>] . As for tobacco, its role in the pancreatic carcinogen has been well established, but its mechanism is poorly elucidated [<xref ref-type="bibr" rid="scirp.78831-ref16">16</xref>] [<xref ref-type="bibr" rid="scirp.78831-ref17">17</xref>] [<xref ref-type="bibr" rid="scirp.78831-ref18">18</xref>] . Chronic alcoholism causes chronic pancreatic disease and chronic disease [<xref ref-type="bibr" rid="scirp.78831-ref19">19</xref>] [<xref ref-type="bibr" rid="scirp.78831-ref20">20</xref>] . Clinical manifestations of this condition are not very specific; they are dominated in our series by epigastric pain (48%); Jaundice (44.7%) and altered general status (30%). Our results were consistent with those reported in the literature [<xref ref-type="bibr" rid="scirp.78831-ref21">21</xref>] . As in our study, the delayed diagnosis was observed by other authors [<xref ref-type="bibr" rid="scirp.78831-ref8">8</xref>] [<xref ref-type="bibr" rid="scirp.78831-ref9">9</xref>] . Mean time to diagnosis (2.76 months) in our study was close to that of El guesmi [<xref ref-type="bibr" rid="scirp.78831-ref8">8</xref>] . However, other authors reported longer delays, Bouglouga (4.4 months), Mbengue (5 months). This long delay could be explained by the clinical latency and the non-specificity of the clinical signs most often misleading the diagnosis. The cephalic localization, the most frequent (84%) in our series has been reported by Sellam [<xref ref-type="bibr" rid="scirp.78831-ref14">14</xref>] and Raissouni [<xref ref-type="bibr" rid="scirp.78831-ref9">9</xref>] . Contrary to the Western and Asian series [<xref ref-type="bibr" rid="scirp.78831-ref10">10</xref>] [<xref ref-type="bibr" rid="scirp.78831-ref11">11</xref>] , which reported high rates of histological diagnosis; only 8.67% of our patients (13 cases) had histology. It was exclusively a ductal adenocarcinoma as described in the literature [<xref ref-type="bibr" rid="scirp.78831-ref14">14</xref>] [<xref ref-type="bibr" rid="scirp.78831-ref22">22</xref>] . The common practice of interventional endoscopy (Endoscopic Retrograde Cholangiography and Echoendoscopy) in these developed countries making the pancreas more accessible could explain this difference. Fourteen of our patients (9.33%) benefited from surgery; surgery was curative in 35.71% of cases and palliative in 64.29% of the cases. In the majority of cases (90.67%) the treatment was symptomatic. Similar studies in African environment reported a predominance of symptomatic treatment [<xref ref-type="bibr" rid="scirp.78831-ref7">7</xref>] . The overall survival in our series was 26%. Our data are in accordance with the literature [<xref ref-type="bibr" rid="scirp.78831-ref23">23</xref>] . Indeed, according to authors [<xref ref-type="bibr" rid="scirp.78831-ref23">23</xref>] . In spite of the resection Ro the long-term survival does not exceed 25% even in the most experienced centers, making pancreatic cancer a condition with appalling prognosis.</p></sec><sec id="s5"><title>5. Conclusion</title><p>Pancreatic cancer is rare affection with a high mortality rate. The improvement of its prognosis depends on the precocity of the diagnosis by morphological examinations (abdominal scanner) to reduce mortality.</p></sec><sec id="s6"><title>Cite this paper</title><p>Ouattara, A., Kone, S., Soro, D., Assi, C., Allah-Kouadio, E., Bi, R.I.G., Denis, F. and Lohoues-Kouacou, M.-J. (2017) Pancreatic Cancer: Epidemiological, Clinical and Therapeutic Aspects in Abidjan (Ivory Coast). Open Journal of Gastroenterology, 7, 223-229. https://doi.org/10.4236/ojgas.2017.78024</p></sec></body><back><ref-list><title>References</title><ref id="scirp.78831-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Abdelmajid, M., Mongl, M. and Fethic, C. (2000) Traitement chirurgical palliatif du cancer de la tete du pancrea. A propos de 42 cas. La Tunisie Chirurgicale, 12, 66-73.</mixed-citation></ref><ref id="scirp.78831-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Prevost, F., Roos, S., Rousset, J.F., Fourtanier, G. and Escat, J. (2001) Traitement chirurgical des adenocarcinomes de la tête du pancreas et de la region peri-ampullaire. A propos de 213 cas. Annales De Chirurgie, 41, 12-17.</mixed-citation></ref><ref id="scirp.78831-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Stewart, B.W. and Kleihues, P. (2003) World Cancer Report 2003. &lt;br /&gt; 
www.iarc.fr/en/publications/pdfs-online/wcr/2003/</mixed-citation></ref><ref id="scirp.78831-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Coulibaly, S., Keita, K., Sissoko, S.B., Diallo, M., Toure, M. and Sibide, S. (2015) Apport de l’echographie dans le diagnostic des tumeurs du pancreas au service de radiologie du chu du point G. Journal Africain Imagerie Médicale, 7, 163-169.</mixed-citation></ref><ref id="scirp.78831-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Mbengue, M., Kra, M.M., Diouf, M.L., Ka, E.F., Pouye, A., Dangou, J.M., et al. (2000) Apport de l’echographie dans l’epidemiologie, le diagnostic et pronostic du cancer du pancreas au sénégal. JEMU, 24, 225-229.</mixed-citation></ref><ref id="scirp.78831-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Moumen, M., El-alaoui, M.E, Mokhtari, M. and EL Fares, F. (1991) Notre experience du traitement du cancer de la tête du pancreas: A propos de 146 cas. Medicine du Maghreb, 30, 33-36.</mixed-citation></ref><ref id="scirp.78831-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Bouglouga, O., Lawson-Ananissoh, L.M., Bagny, A., Kaaga, L. and Redah, D. (2015) Pancreatic cancer: Epidemiological, clinical, and management aspects in the department of hepatogastroenterology at the Lome Campus teaching hospital (Togo). Médecine et Santé Tropicale, 25, 323-326.</mixed-citation></ref><ref id="scirp.78831-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">El, G.S., Ben, N.S., Afrit, M., Labidi, S. and Boussen, H. (2015) Exocrine Pancreatic carcinoma in Tunisia: A retrospective study about 158 cases. La Tunisie Medicale, 93, 73-75.</mixed-citation></ref><ref id="scirp.78831-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Raissouni, S., Rais, G., Mrabti, H., Raissouni, F., Mouzount, H., Aitelhaj, M., et al. (2012) Pancreatic adenocarcinoma in young adults in a moroccan population. Journal of Gastrointestinal Cancer, 43, 607-611.  
&lt;br /&gt;https://doi.org/10.1007/s12029-012-9407-0</mixed-citation></ref><ref id="scirp.78831-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Hana, T.A., Amani, A.E., Shihab, H.A., Rogini, G. and Glory, B.R. (2013) Pancreatic Cancer: Incidence, Clinical Profile and Frequency of Associated Factors in Kuwait. Alexandria Journal of Medicine, 49, 75-80.  
&lt;br /&gt;https://doi.org/10.1016/j.ajme.2012.06.004</mixed-citation></ref><ref id="scirp.78831-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Qiu, M., Jin, Y., Wei, X., Zhou, Y., Wang, Z., Wang, D., et al. (2016) Pathologic Diagnosis of Pancreatic Adenocarcinoma in the United States: Its Status and Prognostic Value. Journal of Cancer, 7, 694-701. &lt;br /&gt;https://doi.org/10.7150/jca.14185</mixed-citation></ref><ref id="scirp.78831-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Ntagirabiri, R., Niyonkuru, S., Karayuba, R., Ndayisaba, G. and Marerwa, G. (2012) Cancer du pancreas au Burundi, experience du CHU de kamenge. Journal African d’Hépato-Gastroentérologie, 6, 312-314. &lt;br /&gt;https://doi.org/10.1007/s12157-012-0422-3</mixed-citation></ref><ref id="scirp.78831-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Almadi, M.A., Alharbi, O., Ozzam, N., Altayeb, M., Javed, M., Alsaif, F., et al. (2013) Clinical Predictors of Resectability of Pancreatic Adenocarcinoma. Saudi Journal of Gastroenterology, 19, 278-285. &lt;br /&gt;https://doi.org/10.4103/1319-3767.121036</mixed-citation></ref><ref id="scirp.78831-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Sellam, F., Harir, N., Khaled, M.B., Mrabent, N.M., Salah, R. and Diaf, M. (2015) Epidemiology and Risk Factors for Exocrine Pancreatic Cancer in a Northern African Population. Journal of Gastrointestinal Cancer, 46, 126-130.  
&lt;br /&gt;https://doi.org/10.1007/s12029-015-9693-4</mixed-citation></ref><ref id="scirp.78831-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Elena, J.W., Steplowski, E., Yu, K., Hartage, P., Tobias, G.S., Brotzman, M.J., et al. (2013) Diabetes and Risk of Pancreactic Cancer: A Pooled Analysis from the Pancreatic Cancer Cohort Consortium. Cancer Causes Control, 24, 13-25.  
&lt;br /&gt;https://doi.org/10.1007/s10552-012-0078-8</mixed-citation></ref><ref id="scirp.78831-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Fuchs, C.S., Colditz, G.A. and Stampfer, M.J. (1996) A Prospective Study of Cigarette Smoking and the Risk of Pancreatic Cancer. Archives of Internal Medicine, 156, 2255-2260. &lt;br /&gt;https://doi.org/10.1001/archinte.1996.00440180119015</mixed-citation></ref><ref id="scirp.78831-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Lowenfels, A.B. and Maisonneuve, P. (2004) Epidemiology and Prevention of Pancreatic Cancer. Japanese Journal of Clinical Oncology, 34, 238-244.  
&lt;br /&gt;https://doi.org/10.1093/jjco/hyh045</mixed-citation></ref><ref id="scirp.78831-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Randall, E.B., Ulia, B.G., Ugene, Z., Honda, B., Ongyan, D., Iane, S., et al. (2009) Pancreatic Cancer Patients Who Smoke and Drink Are Diagnosed at Younger Ages. Gastroenterology and Hepatology, 7, 1007-1012.</mixed-citation></ref><ref id="scirp.78831-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Mahid, S.S., Minor, K.S. and Stevens, P.L. (2007) The Role of Smoking in Crohn’s Disease as Defined by Clinical Variables. Digestive Diseases and Sciences, 52, 2897-2903. &lt;br /&gt;https://doi.org/10.1007/s10620-006-9624-0</mixed-citation></ref><ref id="scirp.78831-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Maisonneuve, P. and Mullhaupt, B. (2005) Cigarette Smoking Accelerates Progression of Alcoholic Chronic Pancreatis. Gut, 54, 510-514.  
&lt;br /&gt;https://doi.org/10.1136/gut.2004.039263</mixed-citation></ref><ref id="scirp.78831-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Lakatos, G., Balazs, A., Kui, B., Godi, S., Szucs, A., Szentesi, A., et al. (2016) Pancreatic Cancer: Multicenter Prospective Data Collection and Analysis by the Hungarian Pancreatic Study Group. Journal of Gastrointestinal and Liver Diseases, 25, 219-225.</mixed-citation></ref><ref id="scirp.78831-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Qiubo, Z., Linjuan, Z., Yinting, C., Guoda, L., Chenchen, Q., Shaojie, C., et al. (2016) Pancreatic Cancer Epidemiology, Detection and Management. Gastroenterology Research and Practice, 2016, Article ID: 8962321.</mixed-citation></ref><ref id="scirp.78831-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Picozzi, V.J., Kozarek, R.A. and Traverso, L.W. (2003) Interferon-Based Adjuvant Chemoradiation Therapy after Pancreaticoduodenectomy for Pancreatic Adenocarcinoma. The American Journal of Surgery, 185, 476-480.</mixed-citation></ref></ref-list></back></article>